KNSA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kiniksa Pharmaceuticals (KNSA) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. Despite some insider selling, the company's strong revenue growth, bullish moving averages, and positive analyst ratings indicate a favorable long-term outlook.
The stock shows bullish moving averages (SMA_5 > SMA_20 > SMA_200), but the MACD is negative and expanding downward (-0.304), suggesting short-term weakness. RSI is neutral at 38.023, and the stock is trading near its S1 support level of 42.122.
Strong revenue growth in Q4 2025, with a 62% YoY increase.
Positive analyst ratings with price targets of $53 and $62, reflecting confidence in the company's future.
Arcalyst is the first FDA-approved therapy for recurrent pericarditis, targeting a growing market projected to reach $6.8B by 2035.
Insider selling has increased significantly (222.25% in the last month).
Q4 2025 GAAP EPS missed expectations by $0.
MACD indicates short-term bearish momentum.
In Q4 2025, Kiniksa reported $202.1M in revenue, a 62% YoY increase, and a net income of $14.2M. However, EPS of $0.17 missed expectations by $0.16. Cash and short-term investments rose to $414.1M, indicating strong liquidity.
Analysts are bullish on Kiniksa. Wedbush raised its price target to $53 from $50 and maintained an Outperform rating. Canaccord initiated coverage with a Buy rating and a $62 price target, citing the company's leadership in the pericarditis treatment market.
